Glycomine Raises $115 Million in San Carlos to Advance PMM2-CDG Rare Disease Drug Testing

Glycomine, a San Carlos-based biotech startup, has successfully raised $115 million in a Series B funding round aimed at advancing its drug for PMM2-CDG, a rare glycosylation disorder that affects muscle control. The funding will facilitate deeper testing of the drug, which targets this potentially deadly condition. The announcement comes amid a broader trend of biotech companies securing substantial investments to tackle challenging medical issues, reflecting ongoing confidence in the sector's potential for breakthroughs in rare disease treatments.